The estimated Net Worth of Laurence N Charney is at least $6.41 million dollars as of 12 March 2024. Mr. Charney owns over 22,000 units of TG Therapeutics Inc stock worth over $4,965,333 and over the last 14 years he sold TGTX stock worth over $1,194,205. In addition, he makes $255,000 as Independent Director at TG Therapeutics Inc.
Sign up
Mr. Charney TGTX stock SEC Form 4 insiders trading
Laurence has made over 5 trades of the TG Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 22,000 units of TGTX stock worth $351,340 on 12 March 2024.
The largest trade he's ever made was selling 30,000 units of TG Therapeutics Inc stock on 4 January 2023 worth over $333,000. On average, Laurence trades about 3,881 units every 196 days since 2011. As of 12 March 2024 he still owns at least 215,229 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Charney stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Laurence Charney biography
Laurence Neil Charney CPA serves as Independent Director of the Company. Mr. Charney has served as a business strategist and financial advisor to Boards, CEOs and investors. Previously, from 1970 through June 2007, Mr. Charney was a senior audit partner at Ernst & Young, LLP, a registered public accounting firm, retiring as a practice leader in the Americas Quality and Risk Management Group. Mr. Charney currently serves as a director and audit committee chairman of Kenon Holdings Ltd. In addition, Mr. Charney previously served as a director and audit committee member of Pacific Drillings S.A, Marvel Entertainment, Inc., XTL Biopharmaceuticals, Ltd., and Iconix Brand Group, Inc. In addition to his extensive experience on the boards of various corporate entities, Mr. Charney is also very active on the boards of several non-profit organizations. Mr. Charney graduated with a B.B.A. degree from Hofstra University and completed the Executive MBA in Business program at Columbia University. Based on Mr. Charney’s financial industry experience and in-depth understanding of our business, the Board of Directors believes that Mr. Charney has the appropriate set of skills to serve as a member of the Board.
What is the salary of Laurence Charney?
As the Independent Director of TG Therapeutics Inc, the total compensation of Laurence Charney at TG Therapeutics Inc is $255,000. There are 4 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.
How old is Laurence Charney?
Laurence Charney is 73, he's been the Independent Director of TG Therapeutics Inc since 2012. There are 1 older and 8 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.
What's Laurence Charney's mailing address?
Laurence's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.
Insiders trading at TG Therapeutics Inc
Over the last 13 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss et Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
What does TG Therapeutics Inc do?
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
What does TG Therapeutics Inc's logo look like?
Complete history of Mr. Charney stock trades at Icon et TG Therapeutics Inc
TG Therapeutics Inc executives and stock owners
TG Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Weiss,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael S. Weiss Esq.,
Chairman, CEO & Pres -
Sean Power,
Chief Financial Officer, Treasurer, Corporate Secretary -
Sean A. Power CPA, CPA,
CFO, Corp. Sec. & Treasurer -
Laurence Charney,
Independent Director -
Kenneth Hoberman,
Independent Director -
William Kennedy,
Independent Director -
Daniel Hume,
Independent Director -
Yann Echelard,
Independent Director -
Jenna Bosco,
Senior Vice President - Corporate Communications -
Sagar Lonial,
Independent Director -
Kelly Ross,
Chief Technology Officer -
Adam Waldman,
Chief Commercial Officer -
Dr. Owen A. O'Connor,
Chief Scientific Officer -
Biotechnologies S.A.S.U. Lfb,
10% owner -
Mark Schoenebaum,
Director -
Neil Herskowitz,
Director -
Capital Management, L.P.Kol...,